Echinocystic Acid

Echinocystic Acid

SCHEMBL42864

CC1(C)CC[C@]2(C(=O)O)[C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 4/20 1.00
SIRT5 Q9NXA8 3/20 1.00
CYP3A4 P08684 1/20 1.00
MAPK1 P28482 1/20 1.00
OXTR P30559 1/20 1.00
AVPR1A P37288 1/20 1.00
CD81 P60033 1/20 1.00
PTPN1 P18031 8/20 0.75
PTPN2 P17706 4/20 0.75
POLB P06746 3/20 0.75
PTPN6 P29350 3/20 0.75
RELA Q04206 3/20 0.75
PSMB11 A5LHX3 2/20 0.75
PSMA7 O14818 2/20 0.75
AKR1B10 O60218 2/20 0.75
PLA2G1B P04054 2/20 0.75
PTPRC P08575 2/20 0.75
PTPRF P10586 2/20 0.75
PSMB1 P20618 2/20 0.75
CES1 P23141 2/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Echinocystic Acid SCHEMBL741321 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR
Echinocystic Acid SCHEMBL30467147 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR
Echinocystic Acid SCHEMBL18712289 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR
Echinocystic Acid SCHEMBL4454760 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR
Echinocystic Acid SCHEMBL13629642 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR
Echinocystic Acid SCHEMBL18712288 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR
Echinocystic Acid SCHEMBL18704435 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR
Echinocystic Acid SCHEMBL17030511 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR
Echinocystic Acid SCHEMBL21892162 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR
Echinocystic Acid SCHEMBL30168683 1.00 F3 (1.00) F3SIRT5CYP3A4MAPK1OXTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4652450-A1 METHODS OF QUANTIFYING SAPONINS PRESENT IN PARTICLES COMPRISING SAPONIN AND LIPID Novavax AB (SE) 2025-11-26 EP claimed
US-20250346914-A1 SAPONARIOSIDE BIOSYNTHETIC ENZYMES PLANT BIOSCIENCE LTD (GB) 2025-11-13 US claimed
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
EP-4547833-A1 SAPONARIOSIDE BIOSYNTHETIC ENZYMES Plant Bioscience Limited (GB) 2025-05-07 EP claimed
CN-119546753-A Saponin biosynthetic enzymes 植物生物科学有限公司 2025-02-28 CN claimed
CN-119165087-A Method for detecting multiple components in rhizoma coptidis green particles 上海市第七人民医院(上海中医药大学附属第七人民医院) 2024-12-20 CN claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 WO claimed
CN-119074745-A Hedera helix saponin composition, hedera helix leaf extract comprising the composition and application thereof 浙江康恩贝中药有限公司 2024-12-06 CN claimed
CN-118901366-A Fertilizing method for realizing multi-economic target yield increase of gleditsia sinensis 山西省林业和草原科学研究院 2024-11-08 CN claimed
CN-118702759-A Echinocystic acid derivative and preparation method and application thereof 延边大学 2024-09-27 CN claimed
US-20070014739-A1 Compositions and methods for controlling biofilms and bacterial infections SEQUOIA SCIENCES, INC. 2007-01-18 US claimed
WO-2006019881-A2 COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS ELDRIDGE GARY R (US) 2006-02-23 WO claimed
CN-1216896-C Echinocystic acid preparation, medicinal preparation and new use as medicine TIANYAO SCIENCE TECHNOLOGY CO (CN) 2005-08-31 CN claimed
CN-1438237-A Echinocystic acid preparation, medicinal preparation and new use as medicine TIANYAO SCIENCE TECHNOLOGY CO (CN) 2003-08-27 CN claimed
JP-2001527390-A 2001-12-25 JP claimed
EP-1011655-A1 INHIBITORS OF LEADERLESS PROTEIN EXPORT Ciblex Corporation (US) 2000-06-28 EP claimed
CN-1252716-A Inhibitors of leaderless protein export CIBLEX CORP (US) 2000-05-10 CN claimed
WO-1998037880-A1 INHIBITORS OF LEADERLESS PROTEIN EXPORT CIBLEX CORPORATION (US) 1998-09-03 WO claimed
EP-0317453-B1 MEDICINAL COMPOSITIONS BASED ON FLAVONOIDS AND SAPONINS EXTRACTED FROM CHRYSANTHELLUM, PROCESS FOR THEIR MANUFACTURE AND THERAPEUTICAL USES IPHYM SA Société Anonyme dite : (FR) 1993-02-03 EP claimed
US-4146615-A GLYCOSIDE OF ECHINOCYSTIC ACID, ANALGESIC, ANTIINFLAMMATORY, ANTIULCER LABORATOIRES SARGET (FR) 1979-03-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070014739-A1 Compositions and methods for controlling biofilms and bacterial infections RHOA, ALOX5, BLVRB F3 91/4885SIRT5 981/4885CYP3A4 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.